Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications.

Guido Boerrigter; John C. Burnett

doi:10.1007/s11897-004-0020-9

Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications.

Guido Boerrigter, John C. Burnett

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

Various lines of evidence implicate impaired renal function as an important prognostic indicator in patients with congestive heart failure (CHF). Conventional diuretics may aggravate renal dysfunction and can result in neurohumoral activation. Evolving new therapeutic strategies that enhance renal function include administration of B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration methods. Prospective studies are needed to evaluate whether these new renal-enhancing strategies will improve patient outcome in CHF.

Original language	English (US)
Pages (from-to)	113-120
Number of pages	8
Journal	Current heart failure reports
Volume	1
Issue number	3
DOIs	https://doi.org/10.1007/s11897-004-0020-9
State	Published - Sep 2004

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-004-0020-9

Cite this

@article{3c5a8c8df0c8407b89b5986b31f51e43,

title = "Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications.",

abstract = "Various lines of evidence implicate impaired renal function as an important prognostic indicator in patients with congestive heart failure (CHF). Conventional diuretics may aggravate renal dysfunction and can result in neurohumoral activation. Evolving new therapeutic strategies that enhance renal function include administration of B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration methods. Prospective studies are needed to evaluate whether these new renal-enhancing strategies will improve patient outcome in CHF.",

author = "Guido Boerrigter and Burnett, {John C.}",

note = "Funding Information: This research was supported by grants from the National Institutes of Health (HL 36634), American Heart Association (AHA 0365411Z), Miami Heart Research Institute, Mayo Foundation (Dubai), Marriott Foundation, and an unrestricted grant for cardiovascular research from Bristol-Myers Squibb.",

year = "2004",

month = sep,

doi = "10.1007/s11897-004-0020-9",

language = "English (US)",

volume = "1",

pages = "113--120",

journal = "Current Heart Failure Reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Cardiorenal syndrome in decompensated heart failure

T2 - prognostic and therapeutic implications.

AU - Boerrigter, Guido

AU - Burnett, John C.

N1 - Funding Information: This research was supported by grants from the National Institutes of Health (HL 36634), American Heart Association (AHA 0365411Z), Miami Heart Research Institute, Mayo Foundation (Dubai), Marriott Foundation, and an unrestricted grant for cardiovascular research from Bristol-Myers Squibb.

PY - 2004/9

Y1 - 2004/9

N2 - Various lines of evidence implicate impaired renal function as an important prognostic indicator in patients with congestive heart failure (CHF). Conventional diuretics may aggravate renal dysfunction and can result in neurohumoral activation. Evolving new therapeutic strategies that enhance renal function include administration of B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration methods. Prospective studies are needed to evaluate whether these new renal-enhancing strategies will improve patient outcome in CHF.

AB - Various lines of evidence implicate impaired renal function as an important prognostic indicator in patients with congestive heart failure (CHF). Conventional diuretics may aggravate renal dysfunction and can result in neurohumoral activation. Evolving new therapeutic strategies that enhance renal function include administration of B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration methods. Prospective studies are needed to evaluate whether these new renal-enhancing strategies will improve patient outcome in CHF.

UR - http://www.scopus.com/inward/record.url?scp=23944447170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944447170&partnerID=8YFLogxK

U2 - 10.1007/s11897-004-0020-9

DO - 10.1007/s11897-004-0020-9

M3 - Review article

C2 - 16036034

AN - SCOPUS:23944447170

SN - 1546-9530

VL - 1

SP - 113

EP - 120

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

IS - 3

ER -

Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this